A Sensitive and Robust Assay for Urokinase and Tissue-Type Plasminogen Activators (Upa and Tpa) and Their Inhibitor Type I (Pai-1) in Breast Tumor Cytosols
Restricted accessResearch articleFirst published online January, 1997
A Sensitive and Robust Assay for Urokinase and Tissue-Type Plasminogen Activators (Upa and Tpa) and Their Inhibitor Type I (Pai-1) in Breast Tumor Cytosols
uPA and PAI-1 are becoming established as amongst the most effective markers of poor prognosis for patients with node-negative breast cancer; tPA is an index of longer survival. This paper describes a sensitive ELISA for the measurement of uPA, tPA and PAI-1 in breast cancer cytosols. The structure of the assay involves coating Ab (sheep α-Chicken IgY), catching Ab (chicken α-analyte), tagging Ab (rabbit α-analyte) and detecting Ab (goat α-rabbit IgG) labelled with HRP. The assay has a high degree of accuracy and specificity. Comparison with the American Diagnostica kits shows the results’ equivalence for PAI-1 and tPA. For uPA the results of the assay were twice as high. The assay is sensitive and relatively inexpensive. It is the first published assay to yield strictly comparative values for uPA, tPA and PAI-1 in tissue extracts and is readily subject to external quality control.
DanøK., AndreasenP.A., Grøndahl-HansenJ., KristensenP., NielsenL.S., SkriverL.Plasminogen activators, tissue degradation and cancer.Adv Cancer Res1985; 44: 139–266.
2.
DuffyM.T., O'GradyP., DevaneyD., O'siorainL., FenellyJ.J., LijnenH.J.Urokinase plasminogen activator, a marker for aggressive breast carcinomas: Preliminary report.Cancer1988; 62: 531–3.
3.
JänickeF., SchmittM., HafterR.. Urokinase-type plasminogen activator (uPA) antigen is a predictor of early relapse in breast cancer.Fibrinolysis1990; 4: 69–78.
4.
FoekensJ.A., LookM.P., PetersH.A., van PuttenW.L.J., PortengenH., KlijnJ.G.M.Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 predict poor response to tamoxifen therapy in recurrent breast cancer.J Natl Cancer Inst1995; 87: 751–6.
5.
SpyratosF., MartinP.M., HacèneK.. Multiparametric prognostic evaluation of biological factors in primary breast cancer.J Natl Cancer Inst1992; 84: 1266–72.
6.
CasslénB., ÅstedtB.The plasminogen activation system in ovarian carcinomas.Fibrinolysis1992; 6(Suppl 4): 65–9.
7.
GaneshS., SierC.F., GriffioenG.. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer.Cancer Res1994; 54: 4065–71.
8.
PedersenH., BrünnerN., FrancisD.. Prognostic impact of urokinase, urokinase receptor and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.Cancer Res1994; 54: 4671–5.
9.
HasuiY., MarutsukaK., NishiS., KitadaS., OsadaY., SumiyoshiA.The content of urokinase-type plasminogen activator and tumor recurrence in superficial bladder cancer.J Urol1994; 151: 16–20.
10.
YamashitaJ., OgawaM., YamashitaS.. Differential biological significance of tissue-type and urokinase-type plasminogen activator in human breast cancer.Br J Cancer1993; 68: 524–9.
11.
MunchM., HeegardC.W., AndreasenP.A.Interconversion between active, inert and substrate forms of denaturated / refolded type-1 plasminogen activator inhibitor.Biochimica et Biophysica Acta1993; 1202: 29–37.
12.
PoisonA., CoetzerT., KrugerJ., von MaltzahnE., van der MerweK.J.Improvements in the isolation of IgY from the yolks of eggs laid by immunized hens.Immunol Invest1985; 14: 323–7.
13.
BradfordM.M.A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.Anal Biochem1976; 72: 248–54.
14.
Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second EORTC workshop, held on 16–17 March, 1979, in the Netherlands Cancer Institute.Eur J Cancer1980; 16: 1513–5.
15.
DaviesC.Concepts: Correlation and method comparison. In: WildD., ed. The immunoassay handbook, 1st ed.New York: Stockton Press, 1994: 83–116.
16.
EkinsR.P.The precision profile: its use in assay design, assessment and quality control. In: HunterW.M., and CorrieJ.E.T., eds. Immunoassays for clinical chemistry, 2nd ed.Edinburgh: Churchill - Livingstone, 1983: 76–105.
17.
PassingH., BablokW.A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, Part I.J Clin Chem Clin Biochem1983; 21: 709–20.
18.
PassingH., BablokW.Comparison of several regression procedures for method comparison studies and determination of sample sizes. Application of linear regression procedures for method comparison studies in clinical chemistry, Part II.J Clin Chem Clin Biochem1984; 22: 431–45.
19.
BlandJ.M., AltmanD.G.Statistical methods for assessing agreement between two methods of clinical measurement.Lancet1986, 1: 307–10.
20.
ButlerJ.E., NiL., NesslerR.. The physical and functional behavior of capture antibodies adsorbed on polystyrene.J Immunol Methods1992; 150: 77–90.
21.
ButlerJ.E., NiL., BrownW.R.. The immunochemistry of sandwich ELISAs - VI. Greater than 90% of monoclonal and 75% of polyclonal anti-fluorescyl capture antibodies (CAbs) are denaturated by passive adsorption.Mol Immunol1993; 30: 1165–75.
22.
ZeissC.R., PruzanskyJ.J., PattersonR., RobertsM.A solid phase radioimmunoassay for the quantitation of human reaginic antibody against ragweed antigen E.J Immunol1973; 110: 414–21.
23.
KoertgeT.E., ButlerJ.E.The relationship between the binding of primary antibody to solidphase antigen in microtiter plates and its detection by the ELISA.J Immunol Methods1985; 83: 283–99.
24.
BenraadT.B., Geurts-MoespotJ., Gröndahl-HansenJ.. Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): Report of an EORTCl/Biomed-1 workshop.Eur J Cancer1996; 32A: 1371–81.
25.
BoscatoL.M., StuartM.C.Incidence and specificity of interference in two-site immunoassays.Clin Chem1986; 34: 27–31.
26.
LarssonA., Karlsson-ParraA., SjöquistJ.Use of chicken antibodies in enzyme immunoassays to avoid interference by rheumatoid factors.Clin Chem1991; 37: 411–4:
